Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Autor:	Aljehani NS; College of Medicine, Jazan University, Jazan, SAU., Al-Gunaid ST; College of Medicine, Syiah Kuala University, Banda Aceh, IDN., Hobani AH; College of Medicine, Jazan University, Jazan, SAU., Alhinti MF; College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, SAU., Khubrani YA; Applied Medical Science and Diagnostic Radiography Technology, Albaha Health Cluster, Albaha, SAU., Abu-Hamoud LM; College of Pharmacy, Taibah University, Madinah, SAU., Alrayes AA; College of Medicine, Jouf University, Jouf, SAU., Alharbi LB; College of Medicine, University of Jeddah, Jeddah , SAU., Sultan AA; College of Medicine, King Khalid University, Abha, SAU., Turkistani DA; College of Medicine, Batterjee Medical College, Jeddah, SAU., Naiser SS; College of Medicine, Xi'an Jiaotong University, Xi'an, CHN., Albraik L; College of Medicine, Alfaisal University, Riyadh, SAU., Alakel AM; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU., Alotaibi M; College of Medicine, Alfaisal University, Riyadh, SAU., Asiri AY; College of Medicine, King Khalid University, Abha, SAU.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Aug 28; Vol. 16 (8), pp. e68008. Date of Electronic Publication: 2024 Aug 28 (Print Publication: 2024).
DOI:	10.7759/cureus.68008
Abstrakt:	The blood-brain barrier (BBB) presents a significant challenge in treating Alzheimer's disease, as it restricts the delivery of therapeutic medications to brain tissue. Reversible breaking of the BBB using low-intensity focused ultrasound guided by magnetic resonance imaging (MRI) may benefit patients with Alzheimer's disease and other neurological illnesses, such as brain tumors, amyotrophic lateral sclerosis, and Parkinson's disease. This systematic study and meta-analysis aimed to assess aducanumab and the ultrasonography of BBB opening in Alzheimer's patients. According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), the study was conducted by searching six digital repositories for relevant scholarly literature, focusing on English papers published between 2015 and 2024; the data was extracted using an Excel sheet, and data was analyzed using Revman 5.4.1 software. The study's findings indicate that the groups receiving ultrasound and aducanumab treatment benefited from it; however, overall, the effect was not statistically significant (P=0.29) at 95% CI 0.86 (0.75, 1.00). With regard to side effects, the results indicate that the treatment had fewer side effects compared to the control group; however, the difference was not statistically significant (p=0.94) at 95% CI 0.93 (0.70, 1.22). The study found a positive effect of ultrasound and aducanumab on the treatment groups, but it was not statistically significant. The control group had less side effects than the treatment group. Therefore, future studies should focus on the quantity or combination of the drug that yields more effective results. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Aljehani et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu